Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.74 |
| ▸ | CA2 | P00918 | 3/20 | 0.74 |
| ▸ | CA9 | Q16790 | 1/20 | 0.74 |
| ▸ | PTGES2 | Q9H7Z7 | 15/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27944569 | 0.86 | CA1 (0.78) | CA1CA2CA9PTGES2 | |
| SCHEMBL3779868 | 0.85 | CA1 (1.00) | CA1CA2CA9PTGES2 | |
| SCHEMBL7589405 | 0.84 | MEN1 (0.59) | CA1CA2 | |
| SCHEMBL3782482 | 0.84 | CA1 (0.74) | CA1CA2CA9PTGES2 | |
| SCHEMBL3779817 | 0.84 | CA2 (0.74) | CA1CA2CA9PTGES2 | |
| SCHEMBL3772475 | 0.83 | PTGES2 (0.70) | CA1CA2CA9PTGES2 | |
| SCHEMBL3782830 | 0.81 | CA1 (1.00) | CA1CA2CA9PTGES2 | |
| SCHEMBL3777574 | 0.80 | PTGES2 (1.00) | CA1CA2CA9PTGES2 | |
| SCHEMBL3778258 | 0.80 | CA2 (0.68) | CA1CA2CA9PTGES2 | |
| SCHEMBL15145878 | 0.80 | MEN1 (0.52) | CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145380-B2 | Bis-(sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2015-09-29 | — | — | US | claimed |
| EP-2234993-B1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2012-11-07 | — | — | EP | claimed |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | claimed |
| EP-2234993-A1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | claimed |
| WO-2009082347-A1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | claimed |
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | claimed |
| US-9145380-B2 | Bis-(sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2015-09-29 | — | — | US | disclosed |
| EP-2234993-B1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2012-11-07 | — | — | EP | disclosed |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| EP-2234993-A1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009082347-A1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | PTGER1, SULT2A1, SULT1E1 | CA1 3346/4885CA2 2435/4885CA9 3411/4885 |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | PTGER1, SULT2A1, SULT1E1 | CA1 3319/4885CA2 2457/4885CA9 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.